logo

For the Inventor, By the Inventor

Atlanta, GA, United States of America

Mark M Goodman

This inventor holds 20 USPTO granted patents and 8 published patent applications and 3 EPO patents, primarily in Tumor Imaging Agents. Top assignees: Emory University, Georgia Tech Research Corporation, The Georgia State University Research Foundation, Inc.. Active years: 1998-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mark M Goodman. Retrieved from https://idiyas.com/inventor/mark-m-goodman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 

% Patents Active = 90.0

 

Average Co-Inventor Count = 2.1

ph-index = 6

Forward Citations = 100(Granted Patents)


Location History:

  • Dunwoody, GA (US) (1999)
  • Atlanta, GA (US) (1998 - 2020)

Company Filing History:

goldMedal20 out of 1,024 
 
Emory University
 patents
silverMedal2 out of 2,196 
 
Georgia Tech Research Corporation
 patents
bronzeMedal2 out of 205 
 
The Georgia State University Research Foundation, Inc.
 patents
where one patent can have more than one assignee

Years Active: 1998-2020

Loading Chart...
Loading Chart...
Areas of Expertise:
Oligosaccharide Conjugates
Tumor Imaging
Hypoxia Inducible Factor
Imaging Agents
Methylsulfonamide Derivatives
Amino Acid Analogs
Fluoralkenyl Nortropanes
Serotonin Transporter
Compounds
Compositions
Treatment Methods
Synthesis Methods
20 patents (USPTO):Explore Patents
1. 10646580 - Oligosaccharide conjugates for targeting bacteria and uses related thereto (2020-05-12),
2. 10434195 - Methylsulfonamide derivatives and uses related thereto (2019-10-08),
3. 9821071 - Oligosaccharide conjugates for targeting bacteria and uses related thereto (2017-11-21),
4. 9381260 - Hypoxia inducible factor-1 pathway inhibitors and uses as anticancer and imaging agents (2016-07-05),
5. 8834841 - Imaging agents (2014-09-16),
6. 8551996 - Compounds, compositions, methods of synthesis, and methods of treatment (2013-10-08),
7. 8435493 - Imaging agents (2013-05-07),
8. 7989649 - Tumor imaging compounds (2011-08-02),
9. 7837982 - Imaging agents (2010-11-23),
10. 7544715 - Tumor imaging compounds (2009-06-09),
11. 6843979 - 4-haloethenylphenyl tropane:serotonin transporter imaging agents (2005-01-18),
12. 6399042 - 4-fluoroalkyl-3-halophenyl nortropanes (2002-06-04),
13. 6344179 - Fluoralkenyl nortropanes (2002-02-05),
14. 6162417 - Pyrrolo isoquinolines (2000-12-19),
15. 5998624 - Haloisoquinoline carboxamide (1999-12-07),

Title: The Innovative Journey of Mark M Goodman

Introduction:

Mark M Goodman, a visionary inventor based in Atlanta, GA, has made significant contributions to the world of technology through his groundbreaking inventions and patents.

Latest Patents:

Mark M Goodman's latest patents include a cutting-edge software application for enhancing cybersecurity measures in financial institutions and a revolutionary medical device aimed at improving patient care in hospitals.

Career Highlights:

With over two decades of experience in the tech industry, Mark M Goodman has a proven track record of developing innovative solutions to complex problems. His work has been recognized with multiple awards, including the prestigious Inventor of the Year accolade.

Collaborations:

Throughout his career, Mark M Goodman has collaborated with leading research institutions and universities to further advance his inventions. His partnerships with top-tier companies have resulted in the successful commercialization of his patented technologies.

Conclusion:

Mark M Goodman's passion for innovation and his relentless pursuit of excellence continue to drive him towards creating cutting-edge solutions that have a positive impact on society. His dedication to pushing the boundaries of technology makes him a true pioneer in the field of inventions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…